[1]Cwynarski K,et al.TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial[J]. Nature Medicine, 2024: 1-7.https://www.nature.com/articles/s41591-024-03326-7 [2]Derigs P,et al.Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic ...
[3] Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial. Retrieved December 11, 2023, from https://www.globenewswire.com/news-release/2023/12/09/2793436/0/en/Corvus-Pharmaceuticals-Presents-New-Interim-Soquelitinib-Data-from-its-Phase-1-...
参考文献: CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023 Jul;29(7):1710-1717. doi: 10.1038/s41591-023-02404-6. Epub 2023 Jul ...
综上,该研究预防性使用anakinra在降低接受CD19靶向的CAR-T细胞治疗的患者的ICANS发生率方面具有很好的活性,为后续临床探索提供了有力的支撑。 推荐阅读原文: CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023.https://doi.org/10.1038/s41591-023-02404-6
当然了，具体的临床实验方案在知乎上肯定是问不到的。Clinical trial上可以搜到一些关于CAR-T临床的简略...
CD7 CAR-T细胞治疗一例特殊染色体异常的复发T淋巴母细胞白血病/淋巴瘤 2021年, 23岁正值意气风发年纪的小尹(化名)不幸确诊为T淋巴母细胞淋巴瘤/白血病,化疗复发,继发高危的耐药的染色体异常……在陆道培医院张弦主任带领团队及时果断的治疗策略下,虽然第一次CAR-T失败,但第二次回输后,CAR-T细胞顺利扩增,病...
Cellular therapy increases survival in recurring B-cell lymphoma: Clinical trial https://medicalxpress.com/news/2024-02-cellular-therapy-survival-recurring-cell.html
4、Park J H, Nath K, Devlin S M, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results[J]. Nature Medicine, 2023: 1-8.
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...